Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic

Molecular Endocrinology

Volumn 23, Issue 3, 2009, Pages 412-421

  Rosenblatt, Adena E ^a   Burnstein, Kerry L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANDROGEN RECEPTOR; ARSENIC; ARSENIC TRIOXIDE; BICALUTAMIDE; CARBOXY TERMINAL TELOPEPTIDE; CYCLIN D; METRIBOLONE;

AMINO TERMINAL SEQUENCE; ANDROGEN RESPONSIVE ELEMENT; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENHANCER REGION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE INFERTILITY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; RECEPTOR DOWN REGULATION; REPORTER GENE; SERTOLI CELL;

ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CELL NUCLEUS; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HUMANS; MALE; NITRILES; NUCLEAR RECEPTOR COACTIVATOR 2; OXIDES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; TOSYL COMPOUNDS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 61449235326     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2008-0235     Document Type: Article

References (53)

1. Hughes MF 2002 Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133:1-16
2. Pant N, Murthy RC, Srivastava SP 2004 Male reproductive toxicity of sodium arsenite in mice. Hum Exp Toxicol 23:399-403
3. Sarkar M, Chaudhuri GR, Chattopadhyay A, Biswas NM 2003 Effect of sodium arsenite on spermatogenesis, plasma gonadotrophins and testosterone in rats. Asian J Androl 5:27-31
4. Centeno JA, Mullick FG, Martinez L, Page NP, Gibb H, Longfellow D, Thompson C, Ladich ER 2002 Pathology related to chronic arsenic exposure. Environ Health Perspect 110:883-886
5. Thomas DJ, Styblo M, Lin S 2001 The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176:127-144
6. Benbrahim-Tallaa L, Waalkes MP 2008 Inorganic arsenic and human prostate cancer. Environ Health Perspect 116:158 -164
7. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S 2002 Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903
8. Lu M, Xia L, Luo D, Waxman S, Jing Y 2004 Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene 23:3945-3952
9. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A 2001 Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61:5432-5440
10. Murgo AJ 2001 Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute cooperative research and development studies. Oncologist 6:22-28
11. Scott N, Hatlelid KM, MacKenzie NE, Carter DE 1993 Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem Res Toxicol 6:102-106
12. Delnomdedieu M, Basti MM, Otvos JD, Thomas DJ 1993 Transfer of arsenite from glutathione to dithiols: a model of interaction. Chem Res Toxicol 6:598-602
13. Kaltreider RC, Davis AM, Lariviere JP, Hamilton JW 2001 Arsenic alters the function of the glucocorticoid receptor as a transcription factor. Environ Health Perspect 109:245-251
14. Lopez S, Miyashita Y, Simons Jr SS 1990 Structurally based, selective interaction of arsenite with steroid receptors. J Biol Chem 265:16039-16042
15. Bodwell JE, Gosse JA, Nomikos AP, Hamilton JW 2006 Arsenic disruption of steroid receptor gene activation: complex dose-response effects are shared by several steroid receptors. Chem Res Toxicol 19:1619-1629
16. Stoica A, Pentecost E, Martin MB 2000 Effects of arsenite on estrogen receptor-α expression and activity in MCF-7 breast cancer cells. Endocrinology 141:3595-3602
17. Benbrahim-Tallaa L, Webber MM, Waalkes MP 2005 Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. Environ Health Perspect 113:1134-1139
18. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
19. Janne OA, Palvimo JJ, Kallio P, Mehto M 1993 Androgen receptor and mechanism of androgen action. Ann Med 25:83-89
20. Heemers HV, Tindall DJ 2007 Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778-808
21. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175-200
22. He B, Lee LW, Minges JT, Wilson EM 2002 Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem 277:25631-25639
23. He B, Wilson EM 2002 The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab 75:293-298
24. Li J, Fu J, Toumazou C, Yoon HG, Wong J 2006 A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol Endocrinol 20:776-785
25. Langley E, Kemppainen JA, Wilson EM 1998 Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 273:92-101
26. Langley E, Zhou ZX, Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983-29990
27. Isomaa V, Parvinen M, Janne OA, Bardin CW Nuclear androgen receptors in different stages of the seminiferous epithelial cycle and the interstitial tissue of rat testis. Endocrinology 116:132-137
28. Vornberger W, Prins G, Musto NA, Suarez-Quian CA 1994 Androgen receptor distribution in rat testis: new implications for androgen regulation of spermatogenesis. Endocrinology 134:2307-2316
29. Brinkmann AO, Jenster G, Ris-Stalpers C, van der Korput JA, Bruggenwirth HT, Boehmer AL, Trapman J 1995 Androgen receptor mutations. J Steroid Biochem Mol Biol 53:443-448
30. Chang C, Chen YT, Yeh SD, Xu Q, Wang RS, Guillou F, Lardy H, Yeh S 2004 Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proc Natl Acad Sci USA 101:6876-6881
31. Burnstein KL 2005 Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95:657-669
32. Debes JD, Tindall DJ 2002 The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 187:1-7
33. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP 2001 Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 98:10823-10828
34. Taplin ME, Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483-490
35. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
36. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E 1992 The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665-669
37. Dai JL, Maiorino CA, Gkonos PJ, Burnstein KL 1996 Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Steroids 61:531-539
38. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM 1995 Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208-218
39. Freedman LP 1999 Strategies for transcriptional activation by steroid/nuclear receptors. J Cell Biochem (Suppl 32-33):103-109
40. Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD, Coetzee GA 2005 GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem 386:69-74
41. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS 2006 Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66:10613-10620
42. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD 2003 Regulation of androgen receptor activity by the nuclear receptor core-pressor SMRT. J Biol Chem 278:5052-5061
43. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L 2005 p53 Represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 276:38472-38479
44. 2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol 19:607-620
45. Ponguta LA, Gregory CW, French FS, Wilson EM 2008 Site specific androgen receptor serine phosphorylation linked to epidermal growth factor dependent growth of castration-recurrent prostate cancer. J Biol Chem 283:20989-21001
46. Carey AM, Pramanik R, Nicholson LJ, Dew TK, Martin FL, Muir GH, Morris JD 2007 Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells. Int J Cancer 121:520-527
47. Hong SH, Privalsky ML 2000 The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol 20:6612-6625
48. Huang C, Ma WY, Li J, Goranson A, Dong Z 1999 Requirement of erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem 274:14595-14601
49. Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ 2001 Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem 276:22177-22182
50. Tanaka-Kagawa T, Hanioka N, Yoshida H, Jinno H, Ando M 2003 Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes. Br J Dermatol 149:1116-1127
51. Mohler JL, Gregory CW, Ford III OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS 2004 The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448
52. Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, Eis V, Urban M, Mandys V 2007 Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72:375-380
53. Grad JM, Dai JL, Wu S, Burnstein KL 1999 Multiple androgen response elements and a myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 13:1896-1911